An open, phase I study of cediranib in patients with acute myeloid leukemia (AML)

被引：0

作者：

Fiedler, Walter ^{[1
]}

Mesters, Rolf ^{[2
]}

Heuser, Michael ^{[3
]}

Ehninger, Gerhard ^{[4
]}

Ottman, Oliver G. ^{[5
]}

Berdel, Wolfgang E. ^{[2
]}

Zirrgiebel, Ute ^{[6
]}

Robertson, Jane ^{[7
]}

Puchalski, Thomas A. ^{[8
]}

Brave, Sandra R. ^{[7
]}

Juergensmeier, Juliane M. ^{[7
]}

Serve, Hubert ^{[2
,5
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Univ Hosp, Munster, Germany

[3] Hannover Med Sch, D-3000 Hannover, Germany

[4] Univ Hosp Carl Gustav Carus, Dresden, Germany

[5] Univ Hosp, Frankfurt, Germany

[6] ProQinase GmbH, Freiburg, Germany

[7] AstraZeneca, Macclesfield, Cheshire, England

[8] AstraZeneca, Wilmington, DE USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.895.895

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

895

引用

页码：273A / 273A

页数：1

共 50 条

[1] An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
Fiedler, Walter
Mesters, Rolf
Heuser, Michael
Ehninger, Gerhard
Berdel, Wolfgang E.
Zirrgiebel, Ute
Robertson, Jane D.
Puchalski, Tom A.
Collins, Barbara
Juergensmeier, Juliane M.
Serve, Hubert
LEUKEMIA RESEARCH, 2010, 34 (02) : 196 - 202
[2] A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
Pollyea, Daniel A.
Kohrt, Holbrook E.
Gallegos, Leonel
Berube, Caroline
Coutre, Steven
Gotlib, Jason
Liedtke, Michaela
Mitchell, Beverly S.
Medeiros, Bruno C.
BLOOD, 2010, 116 (21) : 1347 - 1347
[3] A phase I study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML)
Yee, Karen W.
Brandwein, Joseph
Minden, Mark D.
Sanfelice, Deborah
Chow, Sue
Hedley, David W.
Schimmer, Aaron D.
Schuh, Andre C.
Gupta, Vikas
Sidor, Carolyn F.
Arnott, Jamie
Fletcher, Graham
Bray, Mark
Chen, Hsiao-Wei Tina
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[4] Acute myeloid leukemia (AML): A study of 516 patients
Kumar, L
Menon, H
Sharma, A
Wadhwa, J
Kumar, R
Kochupillai, V
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 610S - 610S
[5] Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies
Talpaz, M.
Shah, N. P.
Deininger, M. W.
Mauro, M. J.
Flinn, I. W.
Lustgarten, S.
Lindmark, W.
Gozgit, J. M.
Clackson, T.
Turner, C. D.
Haluska, F. G.
Kantarjian, H.
Cortes, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] A phase I study of busulfan consolidation/intensification therapy for patients with high risk acute myeloid leukemia (AML).
Gharibo, M. M.
Schaar, D.
Rubin, A.
Grospe, S.
Dudek, L.
Strair, R.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
[7] A phase I study of elesclomol sodium in patients with acute myeloid leukemia
Hedley, David
Shamas-Din, Aisha
Chow, Sue
Sanfelice, Deborah
Schuh, Andre C.
Brandwein, Joseph M.
Seftel, Matthew D.
Gupta, Vikas
Yee, Karen W. L.
Schimmer, Aaron D.
LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2437 - 2440
[8] Phase I study of amonafide plus cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML).
Allen, SL
Kolitz, JE
Lundberg, A
Champagne, M
Devost, S
Dubon, R
Drouin, M
Boss, MA
Grieshaber, CK
Budman, DR
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 585S - 585S
[9] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
Navada, S. C.
Garcia-Manero, G.
Hearn, K.
Odchimar-Reissig, R.
Demakos, E.
Alvarado, Y.
Daver, N.
DiNardo, C.
Konopleva, M.
Borthakur, G.
Azarnia, N.
Silverman, L. R.
LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
[10] Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Badar, Talha
Murthy, Guru Subramanian Guru
Runaas, Lyndsey
Carlson, Karen-Sue B.
Michaelis, Laura C.
Harrington, Alexandra M.
Atallah, Ehab L.
Abedin, Sameem
BLOOD, 2019, 134

← 1 2 3 4 5 →